Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献17篇:

客户使用该产品的5个实验数据:

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M4fWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7xWZcyUUN3ME21Mlg3PjZizszN NFTyNGJUSU6JRWK=
DOHH-2 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\vXYhKSzVyPUmuN|U3QDlizszN M4jwRXNCVkeHUh?=
no-10 M1fMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KxR2lEPTB;OT65NFM6KM7:TR?= MXzTRW5ITVJ?
LS-513 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH0VJBKSzVyPUGxMlM2PDdizszN NX65eZJxW0GQR1XS
ALL-PO NIPHXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[wTWM2OD1zMT63O|M1KM7:TR?= MVTTRW5ITVJ?
8-MG-BA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;jRWlEPTB;MUOuNVEzOyEQvF2= NFXmPWZUSU6JRWK=
RPMI-8402 M2fTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK4U3cxUUN3ME2xOU45PTN5IN88US=> M3PCbnNCVkeHUh?=
EoL-1-cell Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4W25bUUN3ME2xPE42QTR6IN88US=> MX;TRW5ITVJ?
NALM-6 M4LWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPNTWM2OD1zOT6wNVY4KM7:TR?= NWS3XmNOW0GQR1XS
DEL MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf0eINKSzVyPUKwMlE1PzFizszN NYnONZJUW0GQR1XS
SR NIrvNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jvZmlEPTB;MkOuOlcyPSEQvF2= MmKzV2FPT0WU
697 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml60TWM2OD1{Nj62NVU2KM7:TR?= M1\BWnNCVkeHUh?=
COLO-829 M3u0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fNPGlEPTB;Mk[uPFQ5OyEQvF2= MmXrV2FPT0WU
EVSA-T M3zZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjN[|VNUUN3ME2yO{42PTZzIN88US=> M2DVRXNCVkeHUh?=
ATN-1 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nmZmlEPTB;M{GuNlMzQSEQvF2= MUTTRW5ITVJ?
L-363 NFrnXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPJb5ZKSzVyPUOxMlc1PjFizszN MWjTRW5ITVJ?
LAMA-84 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN{LkWyNVEh|ryP MU\TRW5ITVJ?
NOS-1 NHLSXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN2LkK5OVYh|ryP M2jKenNCVkeHUh?=
BB30-HNC NHHJ[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTN2LkOzNFYh|ryP MoLBV2FPT0WU
BC-1 NEKxSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHvVY1SUUN3ME2zO{46PzR4IN88US=> NXO2[IZRW0GQR1XS
IST-SL2 M3PYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHDWIlKSzVyPUO4MlIzPCEQvF2= MmT1V2FPT0WU
D-392MG MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRyLkKyNVUh|ryP NG\ObYJUSU6JRWK=
no-11 NE\uPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q4c2lEPTB;NECuOVUzOSEQvF2= NWHXRm9oW0GQR1XS
LC4-1 NIe3bpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXIVZZKSzVyPUSwMlg4OTZizszN NWS4WpljW0GQR1XS
A388 NEPCRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR{LkW4OFgh|ryP Mm\YV2FPT0WU
NTERA-S-cl-D1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3S2lEPTB;NEKuO|A4PCEQvF2= NEjZR2tUSU6JRWK=
CESS NIXqW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTR2LkKyN|Ih|ryP MWnTRW5ITVJ?
RS4-11 NYnEPIhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR7LkC5N|gh|ryP MV7TRW5ITVJ?
MS-1 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVyLkmzOVEh|ryP MXvTRW5ITVJ?
CTV-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGOlhrUUN3ME21NU4xPzRizszN NYHnV4lMW0GQR1XS
D-502MG NX\nclB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1SmlEPTB;NUGuOlI4OSEQvF2= M4flZXNCVkeHUh?=
ML-2 M2DEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjsTWM2OD13Mj65NVk2KM7:TR?= NFr5c5hUSU6JRWK=
SK-NEP-1 NGHH[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OyV2lEPTB;NUOuN|kzOyEQvF2= NF3hWnBUSU6JRWK=
LOXIMVI M2C5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3N3pFUUN3ME21N{42QDh2IN88US=> NV\LW445W0GQR1XS
DJM-1 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSxTWM2OD13Nj6zN|kyKM7:TR?= NVPoOHZ3W0GQR1XS
GI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjBblI2UUN3ME21Ok43OTR7IN88US=> NE\xR2RUSU6JRWK=
IST-MES1 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1iwXGlEPTB;NkCuOVQ6OyEQvF2= M3TVTHNCVkeHUh?=
MV-4-11 NXmzVW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZyLk[1N|gh|ryP MmXTV2FPT0WU
OVCAR-4 M2nL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PzdGlEPTB;NkOuOVY2PyEQvF2= NIfmb49USU6JRWK=
KE-37 M{jYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLwTWM2OD14Nj6yOlY5KM7:TR?= M4DyWXNCVkeHUh?=
D-542MG Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTZ6LkSxN|Uh|ryP MVPTRW5ITVJ?
MHH-PREB-1 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTd{Lki0OFEh|ryP M2TSRnNCVkeHUh?=
MRK-nu-1 M1fHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHaTHZKSzVyPUezMlQ4ODVizszN MVHTRW5ITVJ?
D-247MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMW2lEPTB;N{OuOVQ1OiEQvF2= M1\mcXNCVkeHUh?=
OCI-AML2 M2[1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTd4LkmzOlkh|ryP MVvTRW5ITVJ?
LP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrVTWM2OD16Mj64O|MyKM7:TR?= Mn3xV2FPT0WU
HCC1599 NFjGe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7kTJBKSzVyPUi0MlI5OzdizszN MU\TRW5ITVJ?
KARPAS-45 M2XQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTh2Lk[5PVIh|ryP NH7lXpZUSU6JRWK=
BE-13 M{TYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTl7LkC0O|ch|ryP MWTTRW5ITVJ?
GCIY MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjtUnBKSzVyPUm5MlA6PTRizszN NX\3R3AzW0GQR1XS
BV-173 M1rQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfQd2JZUUN3ME2xNFAvOzJ3IN88US=> NHq1PJZUSU6JRWK=
LB2518-MEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrF[G1yUUN3ME2xNFAvPzh7IN88US=> NX:1eoxnW0GQR1XS
KS-1 NFnaXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H4dWlEPTB;MUCxMlY{QSEQvF2= MUnTRW5ITVJ?
MOLT-16 M4K3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjLUFdKSzVyPUGwOE46QDZizszN M4HCXXNCVkeHUh?=
NCI-H1770 NFHwZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFyOD63PFQh|ryP MWrTRW5ITVJ?
NCI-H82 NW\GcXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLPPZJKSzVyPUGxNE46PzZizszN NFX5fGlUSU6JRWK=
NCCIT MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjIe49KSzVyPUGxNk42OjlizszN NFfqXVhUSU6JRWK=
KALS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zrRWlEPTB;MUG1Mlk1OSEQvF2= M{TI[XNCVkeHUh?=
LB2241-RCC NUDJenhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHZWYVGUUN3ME2xNVYvPjd7IN88US=> NWnPTZdIW0GQR1XS
HH MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTwOnE{UUN3ME2xNVcvOzl3IN88US=> NIjKR4lUSU6JRWK=
HD-MY-Z MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWWWlEPTB;MUG4MlQ5QCEQvF2= MVzTRW5ITVJ?
EB-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrCTWM2OD1zMkOuNFk1KM7:TR?= MUnTRW5ITVJ?
BL-70 NEnxRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXyTWM2OD1zMkOuNVI4KM7:TR?= NXnsUGVNW0GQR1XS
K-562 M3PJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT6TWM2OD1zMk[uNlQ2KM7:TR?= MonzV2FPT0WU
HT-144 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPpTWM2OD1zM{OuNVY1KM7:TR?= NWj4bY9sW0GQR1XS
PF-382 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPHTWM2OD1zM{SuN|YyKM7:TR?= NWPsbnI2W0GQR1XS
RPMI-8226 NG[xOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF|NT6wOFUh|ryP NWfBPHlyW0GQR1XS
NCI-H1355 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF|NT61PFch|ryP M3PoZXNCVkeHUh?=
LXF-289 M1PZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF|OT63PFEh|ryP MlP0V2FPT0WU
NCI-H69 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF2Mj65N|Ih|ryP MVrTRW5ITVJ?
SK-MEL-1 NUSxd3Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7tR29yUUN3ME2xOFcvOTNizszN MlLoV2FPT0WU
KARPAS-299 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj5W3VvUUN3ME2xOFkvOTJizszN NV3DWmZbW0GQR1XS
GB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF2OT6zNlIh|ryP M4nVcnNCVkeHUh?=
CMK M4Gz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLKWodnUUN3ME2xOFkvPTF3IN88US=> M1W0OHNCVkeHUh?=
MPP-89 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfj[VhKSzVyPUG1Ok4xOzVizszN NUm4TIlSW0GQR1XS
KU812 NEe0fHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPITWM2OD1zNkGuPVAzKM7:TR?= M2rWeHNCVkeHUh?=
REH MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF4Mj6xNlUh|ryP MkWyV2FPT0WU
NEC8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHlTWM2OD1zNkWuNFI3KM7:TR?= M4HJc3NCVkeHUh?=
KP-N-YS NWnyN2o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3WTWM2OD1zNkiuN|k2KM7:TR?= M3XEfXNCVkeHUh?=
Ramos-2G6-4C10 NGnFOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLBTm43UUN3ME2xOlkvQTF3IN88US=> MWPTRW5ITVJ?
Becker NGiwWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TOOWlEPTB;MUe0MlE5KM7:TR?= NHT0[5VUSU6JRWK=
LB647-SCLC NX\sWG9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF5NT64OFUh|ryP M3\DXXNCVkeHUh?=
LU-139 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojvTWM2OD1zN{iuNFE6KM7:TR?= MmfMV2FPT0WU
QIMR-WIL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrieIdoUUN3ME2xO|kvPjR4IN88US=> NH7UeXlUSU6JRWK=
NCI-H1395 NYrWNnI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGxT4lKSzVyPUG3PU46QTZizszN MUnTRW5ITVJ?
NOMO-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF6Mj64OUDPxE1? NIPZNo9USU6JRWK=
GI-ME-N NHPFcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P5UWlEPTB;MUi3Mlk3QSEQvF2= MkLCV2FPT0WU
KMS-12-PE MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m5c2lEPTB;MUi5MlI4OyEQvF2= MoDjV2FPT0WU
Daudi M1HPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDhNFJKSzVyPUG5NU4yOjhizszN M37EWXNCVkeHUh?=
LB996-RCC M{\6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX2TWM2OD1zOUGuOlk6KM7:TR?= NFnXbodUSU6JRWK=
NCI-H2107 NWSycldZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{izSGlEPTB;MUmzMlc{QSEQvF2= MWHTRW5ITVJ?
SK-PN-DW M{f6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF7ND63NVkh|ryP MoP3V2FPT0WU
MC-CAR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW0elBKSzVyPUKwNk4zPTNizszN M4DGNXNCVkeHUh?=
SNB75 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr5WoRuUUN3ME2yNlEvQTRizszN NXraSI5jW0GQR1XS
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPzPY5HUUN3ME2yNlMvPzh|IN88US=> MXLTRW5ITVJ?
KARPAS-422 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvwSGlKSzVyPUKyPE4{PTJizszN M3PRU3NCVkeHUh?=
NCI-H1648 NEK1fZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7wTWM2OD1{MkmuOFg6KM7:TR?= MYLTRW5ITVJ?
ES6 NY\sd4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ|OT60N{DPxE1? NYfnc29oW0GQR1XS
KNS-81-FD M1LER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHLTIp1UUN3ME2yOFEvOTl5IN88US=> MVvTRW5ITVJ?
JAR NXzKSHZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ3Nj6yNlUh|ryP MWjTRW5ITVJ?
NB1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zVU2lEPTB;Mk[wMlUyPiEQvF2= NH3Me3hUSU6JRWK=
D-336MG Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXNotKSzVyPUK2NE43QThizszN MXzTRW5ITVJ?
BC-3 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6XmJ4UUN3ME2yOlUvOTd6IN88US=> MWPTRW5ITVJ?
HCC2218 NITCWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnxc41KSzVyPUK2Ok41OTVizszN NYf2Vm44W0GQR1XS
TE-9 NID6bW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SyNmlEPTB;Mk[2MlYzPyEQvF2= NFK2XmNUSU6JRWK=
LB1047-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD1{Nk[uO|U{KM7:TR?= NFPQN3FUSU6JRWK=
CTB-1 NFrmdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ4OT65O|Mh|ryP NXPJd5lzW0GQR1XS
NB7 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmS2lEPTB;MkexJO69VQ>? NViyWncxW0GQR1XS
ST486 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPtXYdKSzVyPUK3O{41OTJizszN M4rpSHNCVkeHUh?=
HCC1187 NI\lOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ6Mj64NVEh|ryP M2\rZ3NCVkeHUh?=
NCI-SNU-16 M4DqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnHWZVKSzVyPUK4OE4zPDhizszN M4OyNXNCVkeHUh?=
COR-L279 M{C2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzhOGVKSzVyPUK5NU42QDRizszN NHfPdGJUSU6JRWK=
ES8 NWH2N29iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLUe|ZKSzVyPUK5OE4yQDJizszN NGTpZ45USU6JRWK=
U-698-M NWfyOVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XvUGlEPTB;Mkm4MlI1OyEQvF2= MV\TRW5ITVJ?
HEL NX\5V3VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNyOT6xOFkh|ryP NIjzdVdUSU6JRWK=
KINGS-1 M1fWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTuVHV7UUN3ME2zNVAvPjd2IN88US=> MXjTRW5ITVJ?
KY821 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jufGlEPTB;M{O2MlU6PSEQvF2= NFLYeVRUSU6JRWK=
MZ1-PC M3S4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN2NT62NVgh|ryP NV;DeWR3W0GQR1XS
LS-411N M2fkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN3ND62OkDPxE1? NVXENJN1W0GQR1XS
SIG-M5 NYi4[Ip[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN3OT63PFIh|ryP M{TiR3NCVkeHUh?=
HT MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrqPXNKSzVyPUO2O{44OTFizszN Mm\5V2FPT0WU
HC-1 NGDL[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ztR2lEPTB;M{[3Mlc5PyEQvF2= MWHTRW5ITVJ?
NCI-H1694 NWm1OItxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fHbmlEPTB;M{eyMlk{PCEQvF2= MVXTRW5ITVJ?
BB65-RCC M4CyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonaTWM2OD1|N{[uNlQ2KM7:TR?= NXn2[ItSW0GQR1XS
HAL-01 NHLlR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrnTWM2OD1|N{muPFM5KM7:TR?= Mkf4V2FPT0WU
ARH-77 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQeGlEPTB;M{m0MlAxQCEQvF2= M{XmdnNCVkeHUh?=
MZ7-mel MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj1fYFKSzVyPUO5O{4zOzNizszN NESzdXFUSU6JRWK=
SIMA MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnlcVZKSzVyPUSwN{46OzNizszN M2T5OHNCVkeHUh?=
DG-75 NY\KN2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRzNT62PVgh|ryP NVfTSJI2W0GQR1XS
HUTU-80 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRzOT6xPFUh|ryP MoTzV2FPT0WU
KNS-42 NG\McHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrCSJMyUUN3ME20NlUvQDF3IN88US=> MmnSV2FPT0WU
SH-4 NUjlc3pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfQTWM2OD12MkeuOVY2KM7:TR?= NVThR2x5W0GQR1XS
L-540 NXjCTm5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTR|MT6wN|Eh|ryP M3zsTHNCVkeHUh?=
NB10 NUPWWm9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPGXpZ3UUN3ME20OFEvOjN2IN88US=> Mn:yV2FPT0WU
ES1 NHn6TlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjzd5BKSzVyPUS1Nk44PTNizszN NYeyXoZUW0GQR1XS
KMOE-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkOYRKSzVyPUS1Ok44OTFizszN M4DoVXNCVkeHUh?=
MC116 NYHibFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLVTWM2OD12NUiuNVE3KM7:TR?= NIr5b|ZUSU6JRWK=
RCC10RGB NXXqbYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTe4tXUUN3ME20OlAvODB3IN88US=> NH3VPGhUSU6JRWK=
RL95-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyUGlEPTB;NE[wMlI{PyEQvF2= NX\YXWpOW0GQR1XS
Raji NEfOUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR4OD6xOFMh|ryP NHz0SWlUSU6JRWK=
CAS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT2TWM2OD12N{KuNFc{KM7:TR?= MXLTRW5ITVJ?
Calu-6 NX:0W3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR5NT6yOlUh|ryP NYnvNY46W0GQR1XS
KG-1 NV;H[mhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17PN2lEPTB;NEe4MlQ1KM7:TR?= NYPSeVFpW0GQR1XS
LB771-HNC NEnWSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\YdoNuUUN3ME20PFIvOjN{IN88US=> NFLVRZVUSU6JRWK=
ACN NFnLXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7aS2RKSzVyPUS5N{42QTlizszN MnTFV2FPT0WU
KM12 M4rDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnhN5ZKSzVyPUS5Ok42QDlizszN NVPNUFdXW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID